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Background: Mesenchymal stem cells have been shown therapeutic in various neurological 
disorders. Recent studies support the notion that the predominant mechanism by which MSCs 
act is through the release of extracellular vesicles (EVs). EVs seem to have similar therapeutic 
activity as their cellular counterparts and may represent an interesting alternative standalone 
therapy for various diseases. The aim of the study was to optimize the method of EV imaging 
to better understand therapeutic effects mediated by EVs.
Methods: The fluorescent lipophilic stain PKH26 and superparamagnetic iron oxide nanopar-
ticles conjugated with rhodamine (Molday ION Rhodamine B™) were used for the labeling of 
vesicles in human bone marrow MSCs (hBM-MSCs). The entire cycle from intracellular vesicles 
to EVs followed by their uptake by hBM-MSCs has been studied. The identity of vesicles has 
been proven by antibodies against: anti-CD9, -CD63, and -CD81 (tetraspanins). NanoSight 
particle tracking analysis (NTA), high-resolution flow cytometric analysis, transmission electron 
microscopy (TEM), ELYRA PS.1 super-resolution microscopy, and magnetic resonance imaging 
(MRI) were used for the characterization of vesicles.
Results: The PKH26 and Molday ION were exclusively localized in intracellular vesicles 
positively stained for EV markers: CD9, CD63, and CD81. The isolated EVs represent hetero-
geneous population of various sizes as confirmed by NTA. The TEM and MRI were capable 
to show successful labeling of EVs using ION. Co-culture of EVs with hBM-MSCs revealed 
their uptake by cells in vitro, as visualized by the co-localization of PKH26 or Molday ION 
with tetraspanins inside hBM-MSCs.
Conclusion: PKH26 and Molday ION seem to be biocompatible with EVs, and the labeling 
did not interfere with the capability of EVs to re-enter hBM-MSCs during co-culture in vitro. 
Magnetic properties of IONs provide an additional advantage for the imaging of EV using 
TEM and MRI.
Keywords: mesenchymal stem cells, extracellular vesicles, cell tracking, fluorescent dye, iron 
oxide, MRI
Introduction
Mesenchymal stem cells (MSCs) are considered as a promising therapeutic agent 
in various disorders. The therapeutic value of MSCs was evident in the number of 
experimental studies1–6 and clinical trials.7 Although it was initially thought that the 
therapeutic effects of MSCs depend on their capabilities for cell replacement, many 
studies have demonstrated that paracrine activity is the predominant mechanism by 
which MSCs participate in tissue repair.8–10 It was shown that by the secretion of 
different bioactive molecules, MSCs may support endogenous stem cell proliferation, 
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reduce apoptosis, promote angiogenesis, and modulate 
immune reactions.11–15 Previous studies have focused on 
characterizing MSC-produced soluble factors, ie, cytokines, 
chemokines, and growth factors, but it has been recently 
documented that MSCs release also large numbers of extra-
cellular vesicles (EVs).16–18 It seems that many therapeutic 
effects of MSCs might be mediated by the EVs.19–22 Increas-
ing evidence indicates that EVs play also an important role 
in cell–cell communications. There are three main classes of 
EVs, such as exosomes, microvesicles, and apoptotic bodies 
with distinct size, density, and composition.23,24 However, 
the dimensions and density of different subtypes of vesicles 
can also overlap. Moreover, lack of specific markers for each 
type of vesicle makes it technically challenging to analyze 
their specific properties. EVs are released from cells under 
physiological and pathological conditions such as during cell 
activation, stress, and apoptosis.25 The subset of bioactive 
molecules harbored in EVs represents the content of parental 
releasing cell. The external stimulation from the surrounding 
microenvironment has been shown to regulate protein pack-
aging into EVs and to affect their functional properties.26
The recent experimental studies reveal that EVs have the 
advantage as therapeutic agents over MSCs in many aspects. 
Cell free, EV-based therapy circumvents the risk associated 
with MSC-based therapies, such as replication competence, 
accumulation of genomic alterations, and genetic instability, 
and clinical-grade EVs have been recently manufactured.27–30 
Moreover, systemically injected MSCs have been shown to 
be an object of immunomediated rejection. In addition, higher 
doses of MSCs delivered intra-arterially may produce adverse 
events such as micro-strokes.31,32 Despite the lack of MHC 
class II expression on the surface of MSCs, their iv infu-
sion leads to immediate activation of innate immune reaction 
resulting in cell lysis and their clearance from the circulation 
within 60 minutes.33,34 In this regard, it will be interesting 
to determine whether EVs derived from MSCs infused sys-
temically become detected by the host and rapidly cleared as 
their parental cells, as well as what is the final destinations 
of injected EVs. For that purpose, the noninvasive imaging 
of EVs in vivo would be beneficial. Advanced microscopy of 
fluorescently labeled EVs using several types of PKH-based 
tracers is a most frequently employed imaging method. The 
labeling with PKH-based tracers is relatively simple and 
fast and enables membranes of already isolated EVs to be 
stained. In recent times, superparamagnetic iron oxide (SPIO) 
nanoparticles have been extensively used preclinically35,36 and 
clinically37 for noninvasive stem cell tracking using magnetic 
resonance imaging (MRI). SPIO nanoparticles were also 
used to label exosomes from mouse B16-F10 melanoma 
cells labeled with SPIO nanoparticles were tracked in MRI 
after injection into the footpad of C57BL/6 mice.38 The ultr-
asmall SPIO (USPIO) was also recently incorporated into 
ASCs, and released EVs were shown to be loaded with this 
magnetic label.39 While the USPIO nanoparticles were easily 
detectable by MRI, the need for using electron microscopy 
(EM) for their postmortem identification makes the analysis 
of EV fate complex, and even more challenging when the 
co-localization of nanoparticles with certain proteins via 
immunostaining is needed. Therefore, the goal of our study 
was to investigate the feasibility and value of using fluo-
rescent and magnetic double-labeled SPIO nanoparticles as 
a tool to image the EV trafficking in vitro as compared to 
PKH-based fluorescent labels as well as a potential to use 
the same label for the monitoring of EV delivery.
Methods
cell culture
Commercially available human bone marrow MSCs (hBM-
MSCs) (Lonza, Walkersville, MD, USA) were plated in 
75 cm2 polystyrene tissue culture flasks (Thermo Fisher 
Scientific, Waltham, MA, USA) at a density of 5×103 cells/cm2 
with 10 mL of Mesenchymal Stem Cell Growth Medium 
(MSCGM™, BulletKit™; Lonza). Cultures were incubated 
at 37°C in a humidified atmosphere containing 5% CO
2
. 
Cells were subsequently maintained in MSCGM™ medium 
and passaged at 80% confluence in a ratio of 1:2 in trypsin/
EDTA solution (Thermo Fisher Scientific) with the culture 
medium changed thrice a week.
labeling of hBM-Mscs
The labeling of cells with Molday ION consisted of SPIO 
nanoparticles, and rhodamine purchased from BioPAL 
(Worcester, MA, USA) was performed as previously 
described by us.35 Briefly, 100 μL of Molday ION was added 
to the 5×105 hBM-MSCs cultured in 10 mL of MSCGM and 
incubated over 16 hours at 37°C in a humidified atmosphere 
containing 5% CO
2
. After that, medium with label was 
removed, cells were washed with phosphate-buffered saline 
(PBS), fresh medium was added, and cells were cultured 
for 48 or 72 hours. The labeling of cells with PKH26 (Red 
Fluorescent Cell Linker Kits MINI26; Sigma-Aldrich Co., 
St Louis, MO, USA) was performed at room temperature 
(RT) for 5 minutes in the dark and blocked with fetal bovine 
serum (FBS), according to manufacturer’s instructions. 
The unincorporated stains were removed by hBM-MSCs 
centrifugation at 400× g for 10 minutes at 20°C–25°C using 
Eppendorf Centrifuge 5804R. hBM-MSCs were washed with 
Dulbecco’s PBS (DPBS) without Ca++ and Mg++ (Lonza) 
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and subjected to additional centrifugation. The pellet was 
re-suspended, and cells were plated in 75 cm2 polystyrene 
tissue culture flasks as described earlier.
Immunocytochemical analysis
Immunocytochemistry was used to identify labeled intracel-
lular vesicles prior to their isolation or after uptake of labeled 
EVs. For phenotypic analysis, indirect immunocytochem-
istry was performed on Molday ION-labeled hBM-MSCs 
and nonlabeled hBM-MSCs previously incubated with 
labeled hBM-MSC-EVs. The direct red fluorescence was 
used to capture the presence of labels and co-localize with 
immunocytochemical staining. The cells were fixed with 
4% paraformaldehyde, blocked, and permeabilized with the 
mixture of 10% goat serum (Thermo Fisher Scientific), 0.1% 
bovine serum albumin (BSA) (Sigma-Aldrich Co.), and 
0.25% Triton (Sigma-Aldrich Co.) for 1 hour at RT. Cells 
were incubated with the following primary mouse antihuman 
monoclonal antibodies: anti-CD73 (1:100; Santa Cruz Bio-
technology Inc., Dallas, TX, USA), anti-CD90 (1:100; Santa 
Cruz Biotechnology Inc.), anti-CD44 (1:100; Santa Cruz 
Biotechnology Inc.), anti-STEM121 (1:100; Cellartis, Takara 
Bio Europe, France), anti-CD63 (1:100; BD Pharmingen), 
anti-CD9 (1:100; BD Pharmingen, New Jersey, USA), and 
anti-CD81 (1:100; Santa Cruz Biotechnology Inc.) overnight 
at 4°C. Then, the secondary goat antimouse antibodies conju-
gated with Alexa Fluor 488 nm/green (Thermo Fisher Scien-
tific) were added and the slides were exposed for 60 minutes 
at RT in the dark. In addition, cell nuclei were counterstained 
with 5 μL (1.33 μg/1 mL) Hoechst 33258 (Sigma-Aldrich 
Co.). After washing with PBS, the slides were mounted 
with Fluorescent Mounting Medium (Dako Denmark A/S, 
Glostrup, Denmark). Negative controls were performed with 
the same procedure omitting the primary antibodies. Imaging 
was performed by super-resolution structured illumination 
microscopy (SR-SIM) on LSM 780/ELYRA PS.1 (Carl 
Zeiss Meditec AG, Jena, Germany) platform equipped with 
the ZEN 2012 software, lasers (488 or 561 nm), and 405 nm 
diode lamp with a 100×, NA 1.46 oil objective. Spherical 
aberration was minimized by choosing an immersion oil with 
a refractive index giving symmetrical point spread functions, 
and image stacks of several micrometer thicknesses were 
taken with 0.100 μm z-steps, five phases, five rotations per 
z-section. The slides analyzed with SR-SIM were registered, 
and the positive cells were counted.
eVs’ isolation from hBM-Mscs
The isolation of EVs was performed from conditioning media 
of Molday ION-labeled and nonlabeled hBM-MSCs. A total 
of 5×106 of hBM-MSCs (passages 4–6) were cultured in 
75 cm2 polystyrene tissue flasks to reach 50%–60% conflu-
ence, then the culture medium was changed, and the cells 
were incubated for additional 48–72 hours to the confluence 
of 70%–80%. Cell culture supernatants were collected and 
centrifuged at 200× g for 10 minutes and then at 500× g for 
10 minutes at 4°C, aliquoted, and frozen at −70°C for further 
use. In order to isolate EVs, hBM-MSCs’ culture superna-
tants were thawed, spun down at 2,000× g for 20 minutes to 
remove cellular debris, and then centrifuged at 100,000× g 
for 75 minutes at 4°C using a Thermo Scientific Type 865 
Fixed Angle Rotor. The pellets were washed with DPBS 
and subjected to an additional centrifugation at 100,000× g 
for 75 minutes at 4°C using a Thermo Scientific Type 865 
Fixed Angle Rotor. Then, the supernatant was discarded and 
the pellet was re-suspended in 100 μL of DPBS and stored 
at −70°C until needed.
labeling of eVs using PKh26
EVs isolated from nonlabeled hBM-MSCs were tagged with 
PKH26 at RT for 5 minutes in the dark and blocked with FBS, 
according to manufacturer’s instructions. The unincorporated 
labels were removed by hBM-MSC-EVs centrifugation at 
100,000× g for 75 minutes at 4°C using a Thermo Scientific 
T-865 Fixed Angle Rotor, Thermo Scientific Sorvall WX 
Ultracentrifuge Series. hBM-MSC-EVs were washed with 
DPBS and subjected to additional centrifugations. Then, the 
pellet was re-suspended in 1 mL of DPBS for further use.
Nanosight particle tracking analysis 
(NTa) of eVs isolated from hBM-Mscs
The size and concentration of hBM-MSC-EVs were analyzed 
using the NanoSight NS300 system (Malvern Instruments, 
Malvern, UK) and configured with scientific CMOS camera 
and blue 488 nm laser. For NanoSight analysis, EVs were 
diluted in 1 mL of DPBS and collected and analyzed by 
the NTA software Version 3.2. Each of six hBM-MSC-EV 
samples from the different isolations was recorded three times 
for 60 seconds at constant temperature 23°C creating three 
replicable histograms, which were averaged.
eVs isolated from hBM-Mscs’ 
characterization by high-resolution 
flow cytometric analysis
Flow cytometry analysis of stained hBM-MSC-EVs was 
performed with Apogee A50-Micro cytometer, unique high-
resolution system dedicated for the reliable characterization 
of small particles. To ensure the specificity of obtained 
data, appropriate isotype controls were also included in 
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gating strategy. hBM-MSC-EVs were stained with the 
following mouse monoclonal antibodies: FITC-conjugated 
anti-CD9 clone M-L13, anti-CD63 clone H5C6, and anti-
CD81 clone JS-81 (all from BD Biosciences, San Jose, CA, 
USA) and PE-conjugated anti-CD44 clone BJ18, anti-CD73 
clone AD2, and anti-CD90 clone 5E10 (all from BioLegend, 
San Diego, CA, USA) or appropriate isotype-match controls. 
Briefly, hBM-MSC-EVs suspended in 0.2 μm filtered PBS 
were incubated with antibodies for 30 minutes at 4°C. Prior 
to addition, all antibodies were centrifuged at 21,000× g for 
20 minutes at 4°C to remove potential protein aggregates. 
Additionally, hBM-MSC-EVs were stained with PKH26 
membrane dye at RT for 5 minutes in the dark and blocked with 
FBS, according to manufacturer’s instructions. The sample of 
PBS only with PKH26 and FBS was also prepared as a control. 
Stained EV samples were analyzed by Apogee A50-Micro flow 
cytometer (Apogee Flow Systems, Hemel Hempstead, UK), 
and the percentage of gated positive events was calculated by 
the Histogram software (Apogee Flow Systems).
Transmission electron microscopy (TeM)
For ultrastructural studies, hBM-MSC-EV pellets were fixed 
with 2% paraformaldehyde (Sigma-Aldrich Co.) and 2.5% 
glutaraldehyde (Merck KGaA, Darmstadt, Germany) in 
0.1 M cacodylate buffer, pH 7.4, overnight at 4°C, postfixed 
with 1% osmium tetroxide (Sigma-Aldrich Co.), dehydrated 
in a graded series of ethanol and propylene oxide (abcr 
GmbH, Karlsruhe, Germany), embedded in Agar 100 resin 
kit R1031 (Agar Scientific Ltd, Stansted, UK), and sectioned 
(50 nm) using ultramicrotome (RMC Boeckeler, Tucson, AZ, 
USA). Ultrathin sections were stained with uranyl acetate 
and lead citrate. Grids were examined with a JEM 1200EX 
electron microscope (Oxford, UK).
MrI analysis
MRI acquisition was performed using the 7T scanner 
(BioSpec 70/30USR; Bruker AXS Inc., Madison, WI, USA). 
For the detection of hBM-MSC-EVs stained with iron nano-
particles, T2-weighted sequence (TR =2,500 ms, TE =36 ms, 
factional anisotropy (FA) =180°, TA =2 minutes 40 seconds) 
was used. For MR imaging of Molday ION-labeled hBM-
MSC-EVs, the pellet of ~1.3×109 EVs diluted in 200 μL of 
DPBS (Lonza) was deposited in PCR tubes and placed in 
the phantom consisting of 2% agar to stabilize the tubes and 
avoid artifacts from surrounding air. hBM-MSC-EVs labeled 
with Molday ION and non-labeled EVs were examined. The 
T2 maps were calculated from the acquired data.
Internalization of eVs into hBM-Mscs
To analyze the transfer of hBM-MSC-EVs into cells, hBM-
MSCs at passage 5 were plated to poly-l-lysine-coated 
coverslips at initial density 103 cells/cm2 maintained at 37°C 
overnight and then incubated with EVs labeled with PKH26 
or Molday ION for 24 hours. After removing media and 
thorough washout of cells, they were fixed and subjected to 
immunocytochemical analysis as described earlier.
Results
characterization of hBM-Mscs
hBM-MSCs have grown in vitro as spindle-shaped cells 
adherent on tissue culture plastic (Figure 1A and B). High 
expansion capacity of hBM-MSCs gives a steady increase 
in total counts of cells reaching 90% confluence after 7 days 
in culture. The human origin of obtained cells was con-
firmed through positive staining by STEM121™ antibody 
(Figure 1C), and their biological identity was proved by 
the abundant expression of combination of surface markers 
specific for MSCs: CD44, CD73, and CD90 (Figure 1D–F). 
This profile remained stable at passages P4, P5, and P6.
Imaging of intracellular vesicles
We have demonstrated that both labels PKH26 and Molday 
ION were successfully uptaken by hBM-MSCs and depos-
ited in the intracellular vesicles, which co-localized with EV 
markers including CD9, CD63, and CD81 (Figure 2). Inter-
estingly, the different image of labeled vesicles is seen using 
these two tracers. The PKH26-labeled vesicles were seen 
yellow indicating the direct co-localization of membranous 
PKH26 label (red) with tetraspanins (green) present on the 
membrane of vesicles. In contrast, the intracellular vesicles 
labeled with Molday ION express red dots visible inside EVs 
surrounded by green areola of positively stained tetraspanins 
present on the membrane of vesicles.
TeM analysis of eVs isolated from 
hBM-Mscs
The ultrastructural analysis of hBM-MSCs confirmed 
the localization of Molday ION in intracellular vesicles 
(Figure 3A–D). Additionally, we have shown Molday ION 
attachment and accumulation at the extracellular membrane. 
Interestingly, some of nanoparticles were captured during 
their uptake by hBM-MSCs and deposition within intracel-
lular vesicles (Figure 3D). The TEM also revealed that EVs 
isolated from hBM-MSCs consist of heterogeneous popula-
tion of vesicles enriched for smaller exosomes and larger 
microvesicles with different sizes and shapes (Figure 4A–C). 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
9.
15
6.
73
.4
2 
on
 1
6-
Au
g-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1657
Imaging of eVs from hBM-Mscs
Figure 1 Morphology of expanded hBM-Mscs after 24 hours (A) and 7 days (B) cell culture in vitro. The immunohistochemical analysis of hBM-Mscs positively stained for 
sTeM121 (C), cD44 (D), cD73 (E), and cD90 (F) proteins (green); cell nuclei were labeled with hoechst (blue). scale bar =50 μm.
Abbreviation: hBM-Mscs, human bone marrow mesenchymal stem cells.
Figure 2 The sr-sIM analysis of hBM-Mscs with intracellular structures visible inside the cells positively stained with lypophilic dyes PKh26 (A–C) or tagged with 
superparamagnetic iron nanoparticles conjugated with rhodamine (Molday ION) (D and E) (red).
Notes: coexpression of tetraspanins (exosome markers), such as cD9 (A and D), cD63 (B and E), and cD81 (C and F) (green), was demonstrated. cell nuclei were 
stained with hoechst (blue). scale bar =50 μm.
Abbreviations: hBM-Mscs, human bone marrow mesenchymal stem cells; sr-sIM, super-resolution structured illumination microscopy.
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???? ??????
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Figure 3 The ultrastructural study of hBM-Mscs labeled with Molday ION.
Notes: The low magnification picture of the entire cell (A), the high magnification of part of cells including cell membrane and both uptaken superparamagnetic iron oxide 
nanoparticles, as well as membrane invagination in the areas of Molday ION accumulation (B and C). Interestingly, the process of internalization of the superparamagnetic 
iron oxide nanoparticles is also captured (D). The red arrows indicate superparamagnetic iron oxide nanoparticles.
Abbreviation: hBM-Mscs, human bone marrow mesenchymal stem cells.
??????
? ? ?
???
??????
?????
??????
?????
??????
Figure 4 TeM analysis of eVs isolated from hBM-Mscs.
Notes: The heterogeneous population of eVs seems to be enriched for exosomes and microvesicles in terms of their size and shape (A–C); the sample of superparamagnetic 
iron oxide nanoparticles (D); and eVs isolated from hBM-Mscs previously tagged with Molday ION show iron particles localized inside (E and F).
Abbreviations: eVs, extracellular vesicles; hBM-Mscs, human bone marrow mesenchymal stem cells; TeM, transmission electron microscopy.
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EVs obtained from Molday ION-tagged hBM-MSCs dem-
onstrated that iron nanoparticles remained inside the vesicles 
after the isolation procedure (Figure 4D–F).
NTa of hBM-Msc-eVs
The NanoSight confirmed the heterogeneity of EV popula-
tion (Figure 5A). The results obtained from six different 
samples and three recordings showed that hBM-MSC-
EVs consisted of two subpopulations: exosomes/smaller 
microvesicles with peak at 111.67±11.55 nm and larger 
microvesicles with peak at 398.33±49.33 nm (Figure 5B). 
Furthermore, most of hBM-MSC-EVs (.80%) had an 
average diameter between 86.73±1.61 and 218.60±2.86 nm 
(Table 1). We have also demonstrated that 5×106 hBM-MSCs 
generated 1.26×109±1.84×107 exosome-enriched particles. 
The concentration corresponded to 110.17±24.00 particles/
frame and 134.87±37.64 centers/frame.
eVs isolated from hBM-Mscs’ 
characterization by high-resolution 
flow cytometric analysis
Comparison of tested samples with the size-defined cali-
brating beads revealed that majority of visualized objects 
possessed size between ~100 and 250 nm. However, we 
observed that only a small subset of analyzed events was 
positive for tetraspanins, with similar amount for CD81 
(2.85%±0.87%) and CD63 (2.58%±1.36%) but the lowest 
expression for CD9 (1.43%±0.46%). In contrast, the analysis 
of surface antigens’ characteristic for MSCs revealed that 
their hBM-MSC-EVs can harbor all three tested markers 
but with differential expression. In particular, the highest 
expression was observed for CD44, reaching 21.32%±3.27% 
of all analyzed particles. Moreover, 16.70±7.44 and 
8.75%±2.03% of acquired EVs contained CD90 and CD73, 
respectively (Figure 6A).
We found that 9.7% of particles present in FBS were 
positive for PKH26, whereas 58.9% of events in EVs sample 
possessed cell-membrane content. Thus, taking into account 
nonspecific particle ballast derived from serum, 49.2% of 
analyzed hBM-MSC-EVs were specifically positive for 
PKH26 membrane staining (Figure 6B).
Mr imaging of eVs isolated from 
hBM-Mscs
The threshold of hBM-MSC-EV visualization determined in 
phantom experiment provided satisfactory signal by MRI. 
While T2-weighted images showed no obvious difference 
between hBM-MSC-EVs labeled with Molday ION and non-
labeled hBM-MSC-EVs, the T2-map revealed the change of 
relaxation time from 974 ms for nonlabeled hBM-MSC-EVs 
? ?
? ?
???
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???
???
???
???
???
?????
???
???
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????
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?????
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??
???????????? ??? ??? ??? ??? ???
????????????
???
??? ??? ??? ?????
Figure 5 eVs’ NTa.
Notes: eVs are observed at the screen shot from NTa video (A). representative graph shows the results of particle concentration and their size measurements. NTa of 
this sample revealed two populations of hBM-Msc-eVs with the peak diameter of 105 and 375 nm (B).
Abbreviations: eVs, extracellular vesicles; hBM-Mscs, human bone marrow mesenchymal stem cells; NTa, Nanosight particle tracking analysis.
Table 1 average data on hBM-Msc-eVs’ size detected by NTa
Size of hBM-MSC-EVs
Mean (nm) Mode (nm) SD (nm) D10 (nm) D50 (nm) D90 (nm)
154.37±1.12 115.13±1.59 69.90±0.38 86.73±1.61 125.23±0.57 218.60±2.86
Note: D10, D50, and D90 values indicate the percentage of particles (10, 50, and 90%, respectively) less than or equal to the adequate particle size.
Abbreviations: eVs, extracellular vesicles; hBM-Msc, human bone marrow mesenchymal stem cell; NTa, Nanosight particle tracking analysis.
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to 253 ms for hBM-MSC-EVs labeled with Molday ION 
(Figure 7).
Uptake of labeled eVs by hBM-Mscs
The SR-SIM analysis showed that labeled EVs were taken 
up by hBM-MSCs after 24 hours of co-culture. It seems that 
PKH26 or Molday ION labeling do not prevent the uptake of 
EVs by MSCs in vitro. The immunofluorescence revealed the 
co-localization of PKH26 or Molday ION with tetraspanins: 
CD9, CD63, and CD81 inside hBM-MSCs (Figure 8).
Discussion
In the present study, EVs were isolated from MSCs and 
their purity, quantity, and visualization in vitro after staining 
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Figure 6 High-resolution flow cytometric analysis of EVs isolated from hBM-MSCs.
Notes: Samples were analyzed by Apogee A50-Micro flow cytometer dedicated for the analysis of small particles. (A) Antigenic profile of EVs. Representative dot plots of 
EVs stained with fluorescent antibodies directed against tetraspanins or mesenchymal stem cell markers. The dot plot of calibrating beads (# 1493) containing the mixture 
of size-defined SL and green PS beads is shown as a size distribution reference. The percentage of objects (gated based on isotype controls) positive for analyzed antigens is 
shown in selected regions (red boxes). (B) representative dot plot of eVs stained with PKh26 membrane dye in the presence of FBs (right), gated to unstained eV sample 
(shown on left). control sample with PKh26 only in the presence of FBs is also shown in the middle. Mals parameter corresponds to the relative size of analyzed objects.
Abbreviations: eVs, extracellular vesicles; FBs, fetal bovine serum; hBM-Mscs, human bone marrow mesenchymal stem cells; Mals, medium angle light scatter; 
Ps, polystyrene; sl, silica.
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with different dyes were determined with currently available 
techniques. Comprehensive characterization of EVs is 
therefore a critical step in the further studies after their 
transplantation.
We have shown that EV labels are vigorously uptaken by 
the hBM-MSCs and trafficked to the intracellular vesicles, 
which co-localize with markers of EVs. It indicates that 
the process of intracellular localization of labels is actively 
regulated, and the deposited labels are ready to be released 
from cells inside EVs. Our observation also indicates that 
this trafficking phenomenon could be also used for screening 
for the new EV labels.
We have used an ultracentrifugation method to isolate 
EVs, which is still a gold standard, and allows getting ultra-
pure population of EVs but is very tedious, time-consuming, 
and cost-ineffective from the perspective of large-scale, 
clinic-driven EV production. Therefore, the specificity of EV 
labeling might be warranted in future for different methods 
Figure 7 In vitro Mr imaging of Molday ION-tracked hBM-Msc-eVs (black arrow) and nonlabeled hBM-Msc-eVs (white arrow) in phantom experiment.
Notes: eV tubes were placed in agar gel (A). No obvious change was visible on echo T2-weighted Mr images (B). The change in relaxation time was detected by T2-map (C).
Abbreviations: eVs, extracellular vesicles; hBM-Msc, human bone marrow mesenchymal stem cell.
Figure 8 The sr-sIM analysis of hBM-Mscs, 24 hours after their co-culture with eVs previously stained with different dyes.
Notes: eVs labeled with PKh26 (A–C) or tagged with Molday ION (D–F) (red) taken up by hBM-Mscs are visible inside the cells. coexpression of tetraspanins: cD9 
(A and D), cD63 (B and E), and cD81 (C and F) (green) were demonstrated. cell nuclei were stained with hoechst (blue). scale bar =20 μm.
Abbreviations: eVs, extracellular vesicles; hBM-Mscs, human bone marrow mesenchymal stem cells; sr-sIM, super-resolution structured illumination microscopy.
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of isolation, especially in case of low EV purity. For example, 
it is possible that labels are attached to the impurities and by 
this way falsely report on the EV destination.
TEM was capable to unequivocally prove the presence 
of Molday ION inside the EVs. Interestingly, Molday ION 
was uniformly distributed inside the EVs in our study, while 
the nonfluorescent USPIO nanoparticles reported by others 
looked rather clumped.40 Further studies to investigate if 
such difference in intravesicular distribution affects their 
therapeutic potential are warranted.
We have shown that labeling dramatically changes T2 
relaxation time of EV suspension in vitro, which is very 
promising for future detailed studies on in vivo EV detection. 
While it has been previously shown that EVs can be detected 
in vivo by MRI, but no quantification of sensitivity or other 
MR parameters was performed.38,39
The distribution of EV size revealed two peaks at 111 
and 398 nm, indicating the existence of two populations of 
EVs. The majority of EV population consists of small EVs 
(.80%), while the large EVs are in minority.
While high-resolution flow cytometry allowed counting 
the PKH26 labeled EVs, it was limited to show the presence 
of tetraspanins’ expression. Importantly, Apogee A50-Micro 
flow cytometer used in this study possesses ~110 nm detec-
tion limits for polystyrene beads and 180 nm for silica beads 
with refractive index more comparable to biological particles. 
Thus, we suppose that the sensitivity of this method is insuf-
ficient to detect such low intensity of fluorescence from the 
antibodies bound to the low-expressed antigens, especially 
present on exosomal fraction of EVs (,100 nm in diameter). 
In contrast, based on the Apogee analysis, we were able 
to detect the MSC surface markers on 10%–20% of EVs. 
Altogether, it may indicate that large EVs including ecto-
somes, which represent 20% of EVs, are shed from the cel-
lular membrane and contain cell membrane surface markers. 
Since they are larger, they are detectable by high-resolution 
flow cytometry. The remaining small EVs, which derive from 
intracellular multivesicular bodies, could not capture enough 
antibodies to generate the signal detectable by the Apogee 
system. Nevertheless, despite some limitations considering 
the detection level, Apogee instrument is still one of the very 
few systems dedicated for the direct cytometric analysis of 
nanoparticles, and its detection is more sensitive compared to 
classical flow cytometers. Additionally, the EV array might 
be an interesting alternative for future studies.40
Although we have shown many important advances in 
EVs’ labeling and imaging, many questions are still needed 
to be answered in future studies. We have shown that labeling 
of hBM-MSCs with PKH26 or Molday ION is an effective 
way to isolate labeled EVs from them. Bright fluorescence 
staining of exosomes, i.e., PKH26 lipophilic dyes allows 
quantitative and qualitative analyses.41,42 However, this 
method is not ideal for the visualization of in vivo adminis-
tration due to high absorption of visible light by the tissues. 
SPIO nanoparticles appear to be ideal cargo candidates for 
EVs due to their small size, biocompatibility, and unique 
magnetic properties. We demonstrated that EVs tagged 
previously by SPIO nanoparticles were visible within cells 
possibly because of their uptake. Our study suggests that 
SPIO nanoparticles do not interfere with the endocytosis of 
labeled hBM-MSC-EVs into cells and their diffusing in local 
microenvironments of cytoplasm. However, the release of 
free iron ions may affect distinct cellular processes and influ-
ences cell physiology. Therefore, further studies need to be 
performed to understand if they are equally therapeutically 
active as nonlabeled EVs.
Conclusion
This is one of the first articles focused on EV labeling to 
provide a convenient tool to study EV trafficking in vitro and 
in vivo. We have shown trafficking of PKH26 and Molday 
ION inside the hBM-MSCs to intracellular vesicles, which 
co-localized with markers of EVs. Then, we were able to con-
firm effective fluorescent labeling of EVs by high-resolution 
flow cytometry and magnetic labeling by TEM and MRI. 
Super-resolution microscopy was instrumental to detect EV 
uptake by hBM-MSCs. The fluorescent and magnetic double 
labeling of EVs by Molday ION is particularly appealing, 
as it allows to visualize EVs both in vitro and in vivo along 
with convenient detection during postmortem analysis and 
co-localization with specific intracellular structures detected 
by immunohistochemistry. The therapeutic activity as well 
as efficacy of uptake of labeled EVs versus nonlabeled EVs 
still needs to be examined in future studies.
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